OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press35010.17650/1818-8346-2019-14-2-70-85BASIC RESEARCHФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ В ПРАКТИЧЕСКОЙ МЕДИЦИНЕ НА СОВРЕМЕННОМ ЭТАПЕThe role of tissue factor in metastasising, neoangiogenesis and hemostasis in cancerРоль тканевого фактора в метастазировании, неоангиогенезе и гемостазе при онкологических заболеванияхKovalenkoT. A.КоваленкоТ. А.
Russian Federation

Build. 2, 1 Leninskie Gory, Moscow 119991, Russia;

4, Kosygina St., Moscow 119991, Russia

Россия, 119991 Москва, ул. Ленинские горы, 1, стр. 2

Россия, 119991 Москва, ул. Косыгина, 4

after-ten@yandex.ruhttps://orcid.org/0000-0002-8128-7757PanteleevM. A.ПантелеевМ. А.
Russian Federation

Build. 2, 1 Leninskie Gory, Moscow 119991, Russia;

4, Kosygina St., Moscow 119991, Russia;

1 Samory Mashela St., Moscow 117997, Russia

Россия, 119991 Москва, ул. Ленинские горы, 1, стр. 2

Россия, 119991 Москва, ул. Косыгина, 4

Россия, 117997 Москва, ул. Саморы Машела, 1

https://orcid.org/0000-0003-4720-7319SveshnikovaA. N.СвешниковаА. Н.
Russian Federation

Build. 2, 1 Leninskie Gory, Moscow 119991, Russia;

4, Kosygina St., Moscow 119991, Russia;

1 Samory Mashela St., Moscow 117997, Russia;

Build. 2, 8 Trubetskaya St., Moscow 119991, Russia

Россия, 119991 Москва, ул. Ленинские горы, 1, стр. 2

Россия, 119991 Москва, ул. Косыгина, 4

Россия, 117997 Москва, ул. Саморы Машела, 1

Россия, 119991 Москва, ул. Трубецкая, 8, стр. 2

Lomonosov Moscow State UniversityФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of SciencesФГБУН «Центр теоретических проблем физико-химической фармакологии РАН»Lomonosov Moscow State UniversityCenter for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of SciencesФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaФГБУН «Центр теоретических проблем физико-химической фармакологии РАН»ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииLomonosov Moscow State UniversityDmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaФГБУН «Центр теоретических проблем физико-химической фармакологии РАН»Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский университет)2607201914270852607201926072019https://oncohematology.abvpress.ru/ongm/article/view/350

Tissue factor, being the main initiator of the blood coagulation in vivo, is involved in a number of physiological processes, such as angiogenesis or cell migration. These processes are not only significant for normal physiology, but also play a role in the development and progression of oncological diseases. This review presents data on the structure of tissue factor, its expression in normal conditions and in cancer, its role in thrombosis development associated with cancer, in angiogenesis and in metastasis. The involvement of tissue factor in such a wide range of physiological processes important for the progression of cancer makes it an attractive target molecule for therapy.

Тканевый фактор, являясь основным инициатором системы свертывания крови in vivo, принимает участие еще в ряде физиологических процессов, таких как ангиогенез или миграция клеток. Данные процессы не только значимы для нормальной физиологии, но и играют роль в развитии и прогрессировании онкологических заболеваний. В настоящем обзоре приведены данные о структуре тканевого фактора, его экспрессии в норме и при онкологических заболеваниях, его роли в развитии тромбоза, ассоциированного с онкологическими заболеваниями, в ангиогенезе опухолевых сосудов и метастазировании. Участие тканевого фактора в таком широком спектре физиологических процессов, важных для прогрессирования онкологического заболевания, делает его привлекательной молекулой-мишенью для терапии.

extrinsic tenaseblood coagulationfactor VIIareceptor PAR2neoplasmвнешняя теназасвертывание кровифактор VIIaрецептор PAR2неоплазияThe study was supported by Russian Basic Research Foundation, grants N 17‑54‑04 009, 17‑00‑00 138 / 17‑00‑00 140 and 18‑34‑20 026.Работа проведена при поддержке грантов Российского фонда фундаментальных исследований 17‑54‑04 009, 17‑00‑00 138 / 17‑00‑00 140 и 18‑34‑20 026Maciel E.O., Carvalhal G.F., da Silva V.D. et al. Increased tissue factor expression and poor nephroblastoma prognosis. J Urol 2009;182(4):1594–9. DOI: 10.1016/j.juro.2009.06.011.Silva D.D., Noronha J.A.P., Silva V.D., Carvalhal G.F. Increased tissue factor expression is an independent predictor of mortality in clear cell carcinoma of the kidney. Int Braz J Urol 2014;40(4):499–506. DOI: 10.1590/S1677-5538.IBJU.2014.04.08.Silva D.D., Noronha J.A.P., Silva V.D., Carvalhal G.F. Increased tissue factor expression is an independent predictor of mortality in clear cell carcinoma of the kidney. Int Braz J Urol 2014;40(4):499–506. DOI: 10.1590/S1677-5538.IBJU.2014.04.08.Davis M.E. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 2016;20(5 Suppl):S2–8. DOI: 10.1188/16.CJON.S1.2-8.Davis M.E. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 2016;20(5 Suppl):S2–8. DOI: 10.1188/16.CJON.S1.2-8.Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163(4):1090–5.Davis M.E. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 2016;20(5 Suppl):S2–8. DOI: 10.1188/16.CJON.S1.2-8.Giesen P.L., Rauch U., Bohrmann B. et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96(5):2311–5. DOI: 10.1073/pnas.96.5.2311.Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163(4):1090–5.Falati S., Liu Q., Gross P. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197(11):1585–98. DOI: 10.1084/jem.20021868.Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163(4):1090–5.Pyo R.T., Sato Y., Mackman N., Taubman M.B. Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration. Thromb Haemost 2004;92(3):451–8. DOI: 10.1160/TH04-02-0122.Giesen P.L., Rauch U., Bohrmann B. et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96(5):2311–5. DOI: 10.1073/pnas.96.5.2311.Bugge T.H., Xiao Q., Kombrinck K.W. et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996;93(13):6258–63. DOI: 10.1073/pnas.93.13.6258.Giesen P.L., Rauch U., Bohrmann B. et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96(5):2311–5. DOI: 10.1073/pnas.96.5.2311.Carmeliet P., Mackman N., Moons L. et al. Role of tissue factor in embryonic blood vessel development. Nature 1996;383(6595): 73–5. DOI: 10.1038/383073a0.Falati S., Liu Q., Gross P. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197(11):1585–98. DOI: 10.1084/jem.20021868.Toomey J.R., Kratzer K.E., Lasky N.M. et al. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88(5):1583–7.Falati S., Liu Q., Gross P. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197(11):1585–98. DOI: 10.1084/jem.20021868.Hembrough T.A., Swartz G.M., Papathanassiu A. et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63(11):2997–3000.Pyo R.T., Sato Y., Mackman N., Taubman M.B. Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration. Thromb Haemost 2004;92(3):451–8. DOI: 10.1160/TH04-02-0122.Khorana A.A., Ahrendt S.A., Ryan C.K. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13(10):2870–5. DOI: 10.1158/1078-0432.CCR-06-2351.Pyo R.T., Sato Y., Mackman N., Taubman M.B. Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration. Thromb Haemost 2004;92(3):451–8. DOI: 10.1160/TH04-02-0122.Sakurai M., Matsumoto K., Gosho M. et al. Expression of tissue factor in epithelial ovarian carcinoma is involved in the development of venous thromboembolism. Int J Gynecol Cancer 2017;27(1):37–43. DOI: 10.1097/IGC.0000000000000848.Bugge T.H., Xiao Q., Kombrinck K.W. et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996;93(13):6258–63. DOI: 10.1073/pnas.93.13.6258.Morrissey J.H., Fakhrai H., Edgington T.S. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987;50(1):129–35. DOI: 10.1016/0092-8674(87)90669-6.Bugge T.H., Xiao Q., Kombrinck K.W. et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996;93(13):6258–63. DOI: 10.1073/pnas.93.13.6258.Harlos K., Martin D.M., O’Brien D.P. et al. Crystal structure of the extracellular region of human tissue factor. Nature 1994;370(6491): 662–6. DOI: 10.1038/370662a0.Carmeliet P., Mackman N., Moons L. et al. Role of tissue factor in embryonic blood vessel development. Nature 1996;383(6595): 73–5. DOI: 10.1038/383073a0.Ohkubo Y.Z., Morrissey J.H., Tajkhorshid E. Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factor. J Thromb Haemost 2010;8(5):1044–3. DOI: 10.1111/j.1538-7836.2010.03826.x.Carmeliet P., Mackman N., Moons L. et al. Role of tissue factor in embryonic blood vessel development. Nature 1996;383(6595): 73–5. DOI: 10.1038/383073a0.Mackman N., Morrissey J.H., Fowler B., Edgington T.S. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry 1989;28(4):1755–62.Toomey J.R., Kratzer K.E., Lasky N.M. et al. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88(5):1583–7.Paborsky L.R., Harris R.J. Post-translational modifications of recombinant human tissue factor. Thromb Res 1990;60(5):367–76. DOI: 10.1016/0049-3848(90)90219-3.Toomey J.R., Kratzer K.E., Lasky N.M. et al. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88(5):1583–7.Bogdanov V.Y., Balasubramanian V., Hathcock J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003;9(4):458–62. DOI: 10.1038/nm841.Hembrough T.A., Swartz G.M., Papathanassiu A. et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63(11):2997–3000.Bogdanov V.Y., Kirk R.I., Miller C. et al. Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost 2006;4(1):158–67. DOI: 10.1111/j.1538-7836.2005.01680.x.Hembrough T.A., Swartz G.M., Papathanassiu A. et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63(11):2997–3000.Fair D.S. Quantitation of factor VII in the plasma of normal and warfarintreated individuals by radioimmunoassay. Blood 1983;62(4):784–91.Khorana A.A., Ahrendt S.A., Ryan C.K. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13(10):2870–5. DOI: 10.1158/1078-0432.CCR-06-2351.Morrissey J.H., Macik B.G., Neuenschwander P.F., Comp P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993;81(3):734–44.Khorana A.A., Ahrendt S.A., Ryan C.K. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13(10):2870–5. DOI: 10.1158/1078-0432.CCR-06-2351.Zwaal R.F., Comfurius P., Bevers E.M. Lipid-protein interactions in blood coagulation. Biochim Biophys Acta 1998;1376(3):433–53. DOI: 10.1016/S0304-4157(98)00018-5Sakurai M., Matsumoto K., Gosho M. et al. Expression of tissue factor in epithelial ovarian carcinoma is involved in the development of venous thromboembolism. Int J Gynecol Cancer 2017;27(1):37–43. DOI: 10.1097/IGC.0000000000000848.Bach R., Gentry R., Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986;25(14):4007–20.Sakurai M., Matsumoto K., Gosho M. et al. Expression of tissue factor in epithelial ovarian carcinoma is involved in the development of venous thromboembolism. Int J Gynecol Cancer 2017;27(1):37–43. DOI: 10.1097/IGC.0000000000000848.O’Brien D.P., Kemball-Cook G., Hutchinson A.M. et al. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry 1994;33(47):14162–9.Morrissey J.H., Fakhrai H., Edgington T.S. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987;50(1):129–35. DOI: 10.1016/0092-8674(87)90669-6.McCallum C.D., Hapak R.C., Neuenschwander P.F. et al. The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. A fluorescence energy transfer study. J Biol Chem 1996;271(45):28168–75.Morrissey J.H., Fakhrai H., Edgington T.S. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987;50(1):129–35. DOI: 10.1016/0092-8674(87)90669-6.Kelley R.F., Costas K.E., O’Connell M.P., Lazarus R.A. Analysis of the factor VIIa binding site on human tissue factor: effects of tissue factor mutations on the kinetics and thermodynamics of binding. Biochemistry 1995;34(33):10383–92.Harlos K., Martin D.M., O’Brien D.P. et al. Crystal structure of the extracellular region of human tissue factor. Nature 1994;370(6491): 662–6. DOI: 10.1038/370662a0.Gibbs C.S., McCurdy S.N., Leung L.L., Paborsky L.R. Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis. Biochemistry 1994;33(47):14003–10.Harlos K., Martin D.M., O’Brien D.P. et al. Crystal structure of the extracellular region of human tissue factor. Nature 1994;370(6491): 662–6. DOI: 10.1038/370662a0.Schullek J.R., Ruf W., Edgington T.S. Key ligand interface residues in tissue factor contribute independently to factor VIIa binding. J Biol Chem 1994;269(30):19399–403.Ohkubo Y.Z., Morrissey J.H., Tajkhorshid E. Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factor. J Thromb Haemost 2010;8(5):1044–3. DOI: 10.1111/j.1538-7836.2010.03826.x.Banner D.W., D’Arcy A., Chene C. et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996;380(6569):41–6. DOI: 10.1038/380041a0.Ohkubo Y.Z., Morrissey J.H., Tajkhorshid E. Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factor. J Thromb Haemost 2010;8(5):1044–3. DOI: 10.1111/j.1538-7836.2010.03826.x.Vadivel K., Agah S., Messer A.S. et al. Structural and functional studies of gamma-carboxyglutamic acid domains of factor VIIa and activated Protein C: role of magnesium at physiological calcium. J Mol Biol 2013;425(11):1961–81. DOI: 10.1016/j.jmb.2013.02.017.Mackman N., Morrissey J.H., Fowler B., Edgington T.S. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry 1989;28(4):1755–62.Drake T.A., Morrissey J.H., Edgington T.S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134(5):1087–97.Mackman N., Morrissey J.H., Fowler B., Edgington T.S. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry 1989;28(4):1755–62.Fleck R.A., Rao L.V., Rapaport S.I., Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990;59(2):421–37.Paborsky L.R., Harris R.J. Post-translational modifications of recombinant human tissue factor. Thromb Res 1990;60(5):367–76. DOI: 10.1016/0049-3848(90)90219-3.Osterud B., Tindall A., Brox J.H., Olsen J.O. Thromboplastin content in the vessel walls of different arteries and organs of rabbits. Thromb Res 1986;42(3):323–29.Paborsky L.R., Harris R.J. Post-translational modifications of recombinant human tissue factor. Thromb Res 1990;60(5):367–76. DOI: 10.1016/0049-3848(90)90219-3.Wilcox J.N., Smith K.M., Schwartz S.M., Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86(8):2839–43. DOI: 10.1073/pnas.86.8.2839.Bogdanov V.Y., Balasubramanian V., Hathcock J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003;9(4):458–62. DOI: 10.1038/nm841.Bom V.J., Bertina R.M. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990;265(2): 327–36. DOI: 10.1042/bj2650327.Bogdanov V.Y., Balasubramanian V., Hathcock J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003;9(4):458–62. DOI: 10.1038/nm841.Rao L.V., Rapaport S.I. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988;85(18):6687–91. DOI: 10.1073/pnas.85.18.668.7Bogdanov V.Y., Kirk R.I., Miller C. et al. Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost 2006;4(1):158–67. DOI: 10.1111/j.1538-7836.2005.01680.x.Kisiel W., Fujikawa K., Davie E.W. Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). Biochemistry 1977;16(19):4189–94.Bogdanov V.Y., Kirk R.I., Miller C. et al. Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost 2006;4(1):158–67. DOI: 10.1111/j.1538-7836.2005.01680.x.Butenas S., Mann K.G. Kinetics of human factor VII activation. Biochemistry 1996;35(6):1904–10. DOI: 10.1021/bi951768c.Fair D.S. Quantitation of factor VII in the plasma of normal and warfarintreated individuals by radioimmunoassay. Blood 1983;62(4):784–91.Nemerson Y., Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res 1985;40(3):351–8. DOI: 10.1016/0049-3848(85)90270-1.Fair D.S. Quantitation of factor VII in the plasma of normal and warfarintreated individuals by radioimmunoassay. Blood 1983;62(4):784–91.Waters E.K., Morrissey J.H. Restoring full biological activity to the isolated ectodomain of an integral membrane protein. Biochemistry 2006;45(11):3769–74. DOI: 10.1021/bi052600m.Morrissey J.H., Macik B.G., Neuenschwander P.F., Comp P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993;81(3):734–44.Neuenschwander P.F., Morrissey J.H. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity. J Biol Chem 1992;267(20):14477–82.Morrissey J.H., Macik B.G., Neuenschwander P.F., Comp P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993;81(3):734–44.Neuenschwander P.F., Fiore M.M., Morrissey J.H. Factor VII autoactivation proceeds via interaction of distinct proteasecofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 1993;268(29):21489–92.Zwaal R.F., Comfurius P., Bevers E.M. Lipid-protein interactions in blood coagulation. Biochim Biophys Acta 1998;1376(3):433–53. DOI: 10.1016/S0304-4157(98)00018-5Ke K., Yuan J., Morrissey J.H. Tissue factor residues that putatively interact with membrane phospholipids. PLoS One 2014;9(2):e88675. DOI: 10.1371/journal.pone.0088675.Zwaal R.F., Comfurius P., Bevers E.M. Lipid-protein interactions in blood coagulation. Biochim Biophys Acta 1998;1376(3):433–53. DOI: 10.1016/S0304-4157(98)00018-5Komiyama Y., Pedersen A.H., Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1990;29(40):9418–25.Bach R., Gentry R., Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986;25(14):4007–20.Versteeg H.H., Heemskerk J.W.M., Levi M., Reitsma P.H. New fundamentals in hemostasis. Physiol Rev 2013;93(1):327–58. DOI: 10.1152/physrev.00016.2011.Bach R., Gentry R., Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986;25(14):4007–20.Шатурный В.И., Шахиджанов С.С., Свешникова А.Н., Пантелеев М.А. Активаторы, рецепторы и пути внутриклеточной сигнализации в тромбоцитах крови. Биомедицинская химия 2014;60(2):198–200. DOI: 10.18097/PBMC20146002182.O’Brien D.P., Kemball-Cook G., Hutchinson A.M. et al. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry 1994;33(47):14162–9.Sato Y., Kataoka H., Asada Y. et al. Overexpression of tissue factor pathway inhibitor in aortic smooth muscle cells inhibits cell migration induced by tissue factor/factor VIIa complex. Thromb Res 1999;94(6):401–6. DOI: 10.1016/S0049-3848(99)00032-8.O’Brien D.P., Kemball-Cook G., Hutchinson A.M. et al. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry 1994;33(47):14162–9.Ueno T., Toi M., Koike M. et al. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000;83(2):164–70. DOI: 10.1054/bjoc.2000.1272.McCallum C.D., Hapak R.C., Neuenschwander P.F. et al. The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. A fluorescence energy transfer study. J Biol Chem 1996;271(45):28168–75.Regina S., Rollin J., Blechet C. et al. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol 2008;3(7):689–97. DOI: 10.1097/JTO.0b013e31817c1b21.McCallum C.D., Hapak R.C., Neuenschwander P.F. et al. The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. A fluorescence energy transfer study. J Biol Chem 1996;271(45):28168–75.Kakkar A.K., Lemoine N.R., Scully M.F. et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995;82(8):1101–4. DOI: 10.1002/bjs.1800820831.Kelley R.F., Costas K.E., O’Connell M.P., Lazarus R.A. Analysis of the factor VIIa binding site on human tissue factor: effects of tissue factor mutations on the kinetics and thermodynamics of binding. Biochemistry 1995;34(33):10383–92.Walker T.M., Van Ginkel P.R., Gee R.L. et al. Expression of angiogenic factors Cyr61 and tissue factor in uveal melanoma. Arch Ophthalmol 2002;120(12):1719–25. DOI: 10.1001/archopht.120.12.1719.Kelley R.F., Costas K.E., O’Connell M.P., Lazarus R.A. Analysis of the factor VIIa binding site on human tissue factor: effects of tissue factor mutations on the kinetics and thermodynamics of binding. Biochemistry 1995;34(33):10383–92.Guan M., Jin J., Su B. et al. Tissue factor expression and angiogenesis in human glioma. Clin Biochem 2002;35(4):321–5. DOI: 10.1016/S0009-9120(02)00312-0.Gibbs C.S., McCurdy S.N., Leung L.L., Paborsky L.R. Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis. Biochemistry 1994;33(47):14003–10.Koizume S., Jin M.-S., Miyagi E. et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006;66(19): 9453–60. DOI: 10.1158/0008-5472.CAN-06-1803.Gibbs C.S., McCurdy S.N., Leung L.L., Paborsky L.R. Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis. Biochemistry 1994;33(47):14003–10.Poon R.T.P., Lau C.P.Y., Ho J.W.Y. et al. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003;9(14):5339–45.Schullek J.R., Ruf W., Edgington T.S. Key ligand interface residues in tissue factor contribute independently to factor VIIa binding. J Biol Chem 1994;269(30):19399–403.Zhao L., Bi Y., Kou J. et al. Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients. J Exp Clin Cancer Res 2016;35:54. DOI: 10.1186/s13046-016-0328-9.Schullek J.R., Ruf W., Edgington T.S. Key ligand interface residues in tissue factor contribute independently to factor VIIa binding. J Biol Chem 1994;269(30):19399–403.Campello E., Spiezia L., Radu C.M. et al. Endothelial, platelet, and tissue factorbearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 2011;127(5):473–7. DOI: 10.1016/j.thromres.2011.01.002.Banner D.W., D’Arcy A., Chene C. et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996;380(6569):41–6. DOI: 10.1038/380041a0.Del Conde I., Bharwani L.D., Dietzen D.J. et al. Microvesicle-associated tissue factor and Trousseau’s syndrome. J Thromb Haemost 2007;5(1):70–4. DOI: 10.1111/j.1538-7836.2006.02301.x.Banner D.W., D’Arcy A., Chene C. et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996;380(6569):41–6. DOI: 10.1038/380041a0.Hron G., Kollars M., Weber H. et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007;97(1):119–23.Vadivel K., Agah S., Messer A.S. et al. Structural and functional studies of gamma-carboxyglutamic acid domains of factor VIIa and activated Protein C: role of magnesium at physiological calcium. J Mol Biol 2013;425(11):1961–81. DOI: 10.1016/j.jmb.2013.02.017.Levitan N., Dowlati A., Remick S.C. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285–91.Vadivel K., Agah S., Messer A.S. et al. Structural and functional studies of gamma-carboxyglutamic acid domains of factor VIIa and activated Protein C: role of magnesium at physiological calcium. J Mol Biol 2013;425(11):1961–81. DOI: 10.1016/j.jmb.2013.02.017.Brandes A.A., Scelzi E., Salmistraro G. et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 1997;33(10):1592–6. DOI: 10.1016/S0959-8049(97)00167-6.Drake T.A., Morrissey J.H., Edgington T.S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134(5):1087–97.Connolly G.C., Menapace L., Safadjou S. et al. Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients. Clin Lung Cancer 2013;14(6): 713–8. DOI: 10.1016/j.cllc.2013.06.003.Drake T.A., Morrissey J.H., Edgington T.S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134(5):1087–97.Sorensen H.T., Mellemkjaer L., Steffensen F.H. et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338(17):1169–73. DOI: 10.1056/NEJM199804233381701.Fleck R.A., Rao L.V., Rapaport S.I., Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990;59(2):421–37.Manly D.A., Wang J., Glover S.L. et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 2010;125(6):511–2. DOI: 10.1016/j.thromres.2009.09.019.Fleck R.A., Rao L.V., Rapaport S.I., Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990;59(2):421–37.Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4–6.Osterud B., Tindall A., Brox J.H., Olsen J.O. Thromboplastin content in the vessel walls of different arteries and organs of rabbits. Thromb Res 1986;42(3):323–29.Ollivier V., Bentolila S., Chabbat J. et al. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998;91(8):2698–703.Osterud B., Tindall A., Brox J.H., Olsen J.O. Thromboplastin content in the vessel walls of different arteries and organs of rabbits. Thromb Res 1986;42(3):323–29.Uusitalo-Jarvinen H., Kurokawa T., Mueller B.M. et al. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007;27(6):1456–62. DOI: 10.1161/ATVBAHA.107.142539.Wilcox J.N., Smith K.M., Schwartz S.M., Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86(8):2839–43. DOI: 10.1073/pnas.86.8.2839.Belting M., Dorrell M.I., Sandgren S. et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10(5):502–9. DOI: 10.1038/nm1037.Wilcox J.N., Smith K.M., Schwartz S.M., Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86(8):2839–43. DOI: 10.1073/pnas.86.8.2839.Thaler J., Preusser M., Ay C. et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res 2013;131(2):162–5. DOI: 10.1016/j.thromres.2012.09.020.Bom V.J., Bertina R.M. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990;265(2): 327–36. DOI: 10.1042/bj2650327.Unruh D., Sagin F., Adam M. et al. Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may help predict aggressive tumor phenotype. Ann Surg Oncol 2015;22(Suppl 3):1206–11. DOI: 10.1245/s10434-015-4592-2.Bom V.J., Bertina R.M. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990;265(2): 327–36. DOI: 10.1042/bj2650327.de Meis E., Azambuja D., Ayres-Silva J.P. et al. Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. Brazilian J Med Biol Res 2010;43(4):403–8. DOI: 10.1590/S0100-879X2010007500017.Rao L.V., Rapaport S.I. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988;85(18):6687–91. DOI: 10.1073/pnas.85.18.668.7Regina S., Valentin J.B., Lachot S. et al. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem 2009;55(10):1834–42. DOI: 10.1373/clinchem.2009.123695.Rao L.V., Rapaport S.I. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988;85(18):6687–91. DOI: 10.1073/pnas.85.18.668.7Nitori N., Ino Y., Nakanishi Y. et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005;11(7):2531–9. DOI: 10.1158/1078-0432.CCR-04-0866.Kisiel W., Fujikawa K., Davie E.W. Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). Biochemistry 1977;16(19):4189–94.Yamashita H., Kitayama J., Ishikawa M., Nagawa H. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol 2007;95:324–31. DOI: 10.1002/jso.20680.Kisiel W., Fujikawa K., Davie E.W. Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). Biochemistry 1977;16(19):4189–94.Abdulkadir S.A., Carvalhal G.F., Kaleem Z. et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000;31(4):443–7. DOI: 10.1053/hp.2000.6547.Butenas S., Mann K.G. Kinetics of human factor VII activation. Biochemistry 1996;35(6):1904–10. DOI: 10.1021/bi951768c.van den Berg Y.W., van den Hengel L.G., Myers H.R. et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci USA 2009;106(46):19497–502. DOI: 10.1073/pnas.0905325106.Butenas S., Mann K.G. Kinetics of human factor VII activation. Biochemistry 1996;35(6):1904–10. DOI: 10.1021/bi951768c.Bieker R., Kessler T., Schwoppe C. et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 2009;113(20):5019–27. DOI: 10.1182/blood-2008-04-150318.Nemerson Y., Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res 1985;40(3):351–8. DOI: 10.1016/0049-3848(85)90270-1.Nilsson F., Kosmehl H., Zardi L., Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61(2):711–6.Nemerson Y., Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res 1985;40(3):351–8. DOI: 10.1016/0049-3848(85)90270-1.Sawada M., Miyake S., Ohdama S. et al. Expression of tissue factor in non-smallcell lung cancers and its relationship to metastasis. Br J Cancer 1999;79(3–4): 472–7. DOI: 10.1038/sj.bjc.6690073.Waters E.K., Morrissey J.H. Restoring full biological activity to the isolated ectodomain of an integral membrane protein. Biochemistry 2006;45(11):3769–74. DOI: 10.1021/bi052600m.Jiang X., Bailly M.A., Panetti T.S. et al. Formation of tissue factor-factor VIIafactor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost 2004;2(1):93–101. DOI: 10.1111/j.1538-7836.2004.00545.x.Waters E.K., Morrissey J.H. Restoring full biological activity to the isolated ectodomain of an integral membrane protein. Biochemistry 2006;45(11):3769–74. DOI: 10.1021/bi052600m.Morris D.R., Ding Y., Ricks T.K. et al. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 2006;66(1):307–14. DOI: 10.1158/0008-5472.CAN-05-1735.Neuenschwander P.F., Morrissey J.H. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity. J Biol Chem 1992;267(20):14477–82.Hjortoe G.M., Petersen L.C., Albrektsen T. et al. Tissue factor-factor VIIa-specific upregulation of IL-8 expression in MDAMB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004;103(8):3029–37. DOI: 10.1182/blood-2003-10-3417.Neuenschwander P.F., Morrissey J.H. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity. J Biol Chem 1992;267(20):14477–82.Tieken C., Verboom M.C., Ruf W. et al. Tissue factor associates with survival and regulates tumour progression in osteosarcoma. Thromb Haemost 2016;115(5):1025–33. DOI: 10.1160/TH15-07-0541.Neuenschwander P.F., Fiore M.M., Morrissey J.H. Factor VII autoactivation proceeds via interaction of distinct proteasecofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 1993;268(29):21489–92.Contrino J., Hair G., Kreutzer D.L., Rickles F.R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2(2):209–15.Neuenschwander P.F., Fiore M.M., Morrissey J.H. Factor VII autoactivation proceeds via interaction of distinct proteasecofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 1993;268(29):21489–92.Ettelaie C., Collier M.E., Featherby S. et al. Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression. Thromb J 2016;14:2. DOI: 10.1186/s12959-016-0075-3.Ke K., Yuan J., Morrissey J.H. Tissue factor residues that putatively interact with membrane phospholipids. PLoS One 2014;9(2):e88675. DOI: 10.1371/journal.pone.0088675.Berny-Lang M.A., Aslan J.E., Tormoen G.W. et al. Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Phys Biol 2011;8(1):15014. DOI: 10.1088/1478-3975/8/1/015014.Ke K., Yuan J., Morrissey J.H. Tissue factor residues that putatively interact with membrane phospholipids. PLoS One 2014;9(2):e88675. DOI: 10.1371/journal.pone.0088675.Goldin-Lang P., Tran Q.V., Fichtner I. et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep 2008;20(1):123–8. DOI: 10.3892/or.20.1.123.Komiyama Y., Pedersen A.H., Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1990;29(40):9418–25.Koomagi R., Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998;79(1):19–22. DOI: 10.1002/(SICI)1097-0215(19980220)79:1<19::AIDIJC4>3.0.CO;2-Z.Komiyama Y., Pedersen A.H., Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1990;29(40):9418–25.Hobbs J.E., Zakarija A., Cundiff D.L. et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007;120(Suppl 2):13–21. DOI: 10.1016/S0049-3848(07)70126-3.Versteeg H.H., Heemskerk J.W.M., Levi M., Reitsma P.H. New fundamentals in hemostasis. Physiol Rev 2013;93(1):327–58. DOI: 10.1152/physrev.00016.2011.Khorana A.A., Francis C.W., Menzies K.E. et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008;6(11):1983–5. DOI: 10.1111/j.1538-7836.2008.03156.x.Versteeg H.H., Heemskerk J.W.M., Levi M., Reitsma P.H. New fundamentals in hemostasis. Physiol Rev 2013;93(1):327–58. DOI: 10.1152/physrev.00016.2011.Thomas G.M., Brill A., Mezouar S. et al. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost 2015;13(7):1310–9. DOI: 10.1111/jth.13002.Shaturnyi V.I., Shakhidzhanov S.S., Sveshnikova A.N., Panteleev M.A. Activators, receptors and signal transduction pathways of blood platelets. Biomeditsinskaya khimiya = Biomedical Chemistry 2014;60(2):198–200. (In Russ.). DOI: 10.18097/PBMC20146002182.Yu J.L., Rak J.W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004;2(11):2065–7. DOI: 10.1111/j.1538-7836.2004.00972.x.Shaturnyi V.I., Shakhidzhanov S.S., Sveshnikova A.N., Panteleev M.A. Activators, receptors and signal transduction pathways of blood platelets. Biomeditsinskaya khimiya = Biomedical Chemistry 2014;60(2):198–200. (In Russ.). DOI: 10.18097/PBMC20146002182.Zhang J., Ding J., Zhang X. et al. Regulation of vascular endothelial growth factor (VEGF) production and angiogenesis by tissue Factor (TF) in SGC-7901 gastric cancer cells. Cancer Biol Ther 2005;4(7):769–72.Sato Y., Kataoka H., Asada Y. et al. Overexpression of tissue factor pathway inhibitor in aortic smooth muscle cells inhibits cell migration induced by tissue factor/factor VIIa complex. Thromb Res 1999;94(6):401–6. DOI: 10.1016/S0049-3848(99)00032-8.Chand H.S., Ness S.A., Kisiel W. Identification of a novel human tissue factor splice variant that is upregulated in tumor cells. Int J Cancer 2006;118(7):1713–20. DOI: 10.1002/ijc.21550.Sato Y., Kataoka H., Asada Y. et al. Overexpression of tissue factor pathway inhibitor in aortic smooth muscle cells inhibits cell migration induced by tissue factor/factor VIIa complex. Thromb Res 1999;94(6):401–6. DOI: 10.1016/S0049-3848(99)00032-8.Del Conde I., Shrimpton C.N., Thiagarajan P., Lopez J.A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005;106(5):1604–11. DOI: 10.1182/blood-2004-03-1095.Ueno T., Toi M., Koike M. et al. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000;83(2):164–70. DOI: 10.1054/bjoc.2000.1272.Rauch U., Bonderman D., Bohrmann B. et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000;96(1):170–5.Ueno T., Toi M., Koike M. et al. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000;83(2):164–70. DOI: 10.1054/bjoc.2000.1272.Hisada Y., Auriemma A.C., Alexander W. et al. Detection of tissue factor-positive extracellular vesicles by laser scanning confocal microscopy. Thromb Res 2017;150:65–72. DOI: 10.1016/j.thromres.2016.12.021.Regina S., Rollin J., Blechet C. et al. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol 2008;3(7):689–97. DOI: 10.1097/JTO.0b013e31817c1b21.Ichikawa J., Cole H.A., Magnussen R.A. et al. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma. Cancer 2012;118(9):2494–506. DOI: 10.1002/cncr.26518.Regina S., Rollin J., Blechet C. et al. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol 2008;3(7):689–97. DOI: 10.1097/JTO.0b013e31817c1b21.Zhang Y., Deng Y., Luther T. et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94(3):1320–7. DOI: 10.1172/JCI117451.Kakkar A.K., Lemoine N.R., Scully M.F. et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995;82(8):1101–4. DOI: 10.1002/bjs.1800820831.Palumbo J.S., Talmage K.E., Massari J.V et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent andindependent mechanisms. Blood 2007;110(1):133–41. DOI: 10.1182/blood-2007-01-065995.Kakkar A.K., Lemoine N.R., Scully M.F. et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995;82(8):1101–4. DOI: 10.1002/bjs.1800820831.Abe K., Shoji M., Chen J. et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96(15):8663–8. DOI: 10.1073/pnas.96.15.8663.Walker T.M., Van Ginkel P.R., Gee R.L. et al. Expression of angiogenic factors Cyr61 and tissue factor in uveal melanoma. Arch Ophthalmol 2002;120(12):1719–25. DOI: 10.1001/archopht.120.12.1719.Bromberg M.E., Sundaram R., Homer R.J. et al. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999;82(1):88–92.Walker T.M., Van Ginkel P.R., Gee R.L. et al. Expression of angiogenic factors Cyr61 and tissue factor in uveal melanoma. Arch Ophthalmol 2002;120(12):1719–25. DOI: 10.1001/archopht.120.12.1719.Guan M., Jin J., Su B. et al. Tissue factor expression and angiogenesis in human glioma. Clin Biochem 2002;35(4):321–5. DOI: 10.1016/S0009-9120(02)00312-0.Guan M., Jin J., Su B. et al. Tissue factor expression and angiogenesis in human glioma. Clin Biochem 2002;35(4):321–5. DOI: 10.1016/S0009-9120(02)00312-0.Koizume S., Jin M.-S., Miyagi E. et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006;66(19): 9453–60. DOI: 10.1158/0008-5472.CAN-06-1803.Koizume S., Jin M.-S., Miyagi E. et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006;66(19): 9453–60. DOI: 10.1158/0008-5472.CAN-06-1803.Poon R.T.P., Lau C.P.Y., Ho J.W.Y. et al. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003;9(14):5339–45.Poon R.T.P., Lau C.P.Y., Ho J.W.Y. et al. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003;9(14):5339–45.Zhao L., Bi Y., Kou J. et al. Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients. J Exp Clin Cancer Res 2016;35:54. DOI: 10.1186/s13046-016-0328-9.Zhao L., Bi Y., Kou J. et al. Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients. J Exp Clin Cancer Res 2016;35:54. DOI: 10.1186/s13046-016-0328-9.Campello E., Spiezia L., Radu C.M. et al. Endothelial, platelet, and tissue factorbearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 2011;127(5):473–7. DOI: 10.1016/j.thromres.2011.01.002.Campello E., Spiezia L., Radu C.M. et al. Endothelial, platelet, and tissue factorbearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 2011;127(5):473–7. DOI: 10.1016/j.thromres.2011.01.002.Del Conde I., Bharwani L.D., Dietzen D.J. et al. Microvesicle-associated tissue factor and Trousseau’s syndrome. J Thromb Haemost 2007;5(1):70–4. DOI: 10.1111/j.1538-7836.2006.02301.x.Del Conde I., Bharwani L.D., Dietzen D.J. et al. Microvesicle-associated tissue factor and Trousseau’s syndrome. J Thromb Haemost 2007;5(1):70–4. DOI: 10.1111/j.1538-7836.2006.02301.x.Hron G., Kollars M., Weber H. et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007;97(1):119–23.Hron G., Kollars M., Weber H. et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007;97(1):119–23.Levitan N., Dowlati A., Remick S.C. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285–91.Levitan N., Dowlati A., Remick S.C. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285–91.Brandes A.A., Scelzi E., Salmistraro G. et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 1997;33(10):1592–6. DOI: 10.1016/S0959-8049(97)00167-6.Brandes A.A., Scelzi E., Salmistraro G. et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 1997;33(10):1592–6. DOI: 10.1016/S0959-8049(97)00167-6.Connolly G.C., Menapace L., Safadjou S. et al. Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients. Clin Lung Cancer 2013;14(6): 713–8. DOI: 10.1016/j.cllc.2013.06.003.Connolly G.C., Menapace L., Safadjou S. et al. Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients. Clin Lung Cancer 2013;14(6): 713–8. DOI: 10.1016/j.cllc.2013.06.003.Sorensen H.T., Mellemkjaer L., Steffensen F.H. et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338(17):1169–73. DOI: 10.1056/NEJM199804233381701.Sorensen H.T., Mellemkjaer L., Steffensen F.H. et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338(17):1169–73. DOI: 10.1056/NEJM199804233381701.Manly D.A., Wang J., Glover S.L. et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 2010;125(6):511–2. DOI: 10.1016/j.thromres.2009.09.019.Manly D.A., Wang J., Glover S.L. et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 2010;125(6):511–2. DOI: 10.1016/j.thromres.2009.09.019.Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4–6.Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4–6.Ollivier V., Bentolila S., Chabbat J. et al. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998;91(8):2698–703.Ollivier V., Bentolila S., Chabbat J. et al. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998;91(8):2698–703.Uusitalo-Jarvinen H., Kurokawa T., Mueller B.M. et al. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007;27(6):1456–62. DOI: 10.1161/ATVBAHA.107.142539.Uusitalo-Jarvinen H., Kurokawa T., Mueller B.M. et al. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007;27(6):1456–62. DOI: 10.1161/ATVBAHA.107.142539.Belting M., Dorrell M.I., Sandgren S. et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10(5):502–9. DOI: 10.1038/nm1037.Belting M., Dorrell M.I., Sandgren S. et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10(5):502–9. DOI: 10.1038/nm1037.Thaler J., Preusser M., Ay C. et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res 2013;131(2):162–5. DOI: 10.1016/j.thromres.2012.09.020.Thaler J., Preusser M., Ay C. et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res 2013;131(2):162–5. DOI: 10.1016/j.thromres.2012.09.020.Unruh D., Sagin F., Adam M. et al. Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may help predict aggressive tumor phenotype. Ann Surg Oncol 2015;22(Suppl 3):1206–11. DOI: 10.1245/s10434-015-4592-2.Unruh D., Sagin F., Adam M. et al. Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may help predict aggressive tumor phenotype. Ann Surg Oncol 2015;22(Suppl 3):1206–11. DOI: 10.1245/s10434-015-4592-2.de Meis E., Azambuja D., Ayres-Silva J.P. et al. Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. Brazilian J Med Biol Res 2010;43(4):403–8. DOI: 10.1590/S0100-879X2010007500017.de Meis E., Azambuja D., Ayres-Silva J.P. et al. Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. Brazilian J Med Biol Res 2010;43(4):403–8. DOI: 10.1590/S0100-879X2010007500017.Regina S., Valentin J.B., Lachot S. et al. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem 2009;55(10):1834–42. DOI: 10.1373/clinchem.2009.123695.Regina S., Valentin J.B., Lachot S. et al. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem 2009;55(10):1834–42. DOI: 10.1373/clinchem.2009.123695.Nitori N., Ino Y., Nakanishi Y. et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005;11(7):2531–9. DOI: 10.1158/1078-0432.CCR-04-0866.Nitori N., Ino Y., Nakanishi Y. et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005;11(7):2531–9. DOI: 10.1158/1078-0432.CCR-04-0866.Yamashita H., Kitayama J., Ishikawa M., Nagawa H. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol 2007;95:324–31. DOI: 10.1002/jso.20680.Yamashita H., Kitayama J., Ishikawa M., Nagawa H. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol 2007;95:324–31. DOI: 10.1002/jso.20680.Abdulkadir S.A., Carvalhal G.F., Kaleem Z. et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000;31(4):443–7. DOI: 10.1053/hp.2000.6547.Abdulkadir S.A., Carvalhal G.F., Kaleem Z. et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000;31(4):443–7. DOI: 10.1053/hp.2000.6547.van den Berg Y.W., van den Hengel L.G., Myers H.R. et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci USA 2009;106(46):19497–502. DOI: 10.1073/pnas.0905325106.van den Berg Y.W., van den Hengel L.G., Myers H.R. et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci USA 2009;106(46):19497–502. DOI: 10.1073/pnas.0905325106.Bieker R., Kessler T., Schwoppe C. et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 2009;113(20):5019–27. DOI: 10.1182/blood-2008-04-150318.Bieker R., Kessler T., Schwoppe C. et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 2009;113(20):5019–27. DOI: 10.1182/blood-2008-04-150318.Nilsson F., Kosmehl H., Zardi L., Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61(2):711–6.Nilsson F., Kosmehl H., Zardi L., Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61(2):711–6.Sawada M., Miyake S., Ohdama S. et al. Expression of tissue factor in non-smallcell lung cancers and its relationship to metastasis. Br J Cancer 1999;79(3–4): 472–7. DOI: 10.1038/sj.bjc.6690073.Sawada M., Miyake S., Ohdama S. et al. Expression of tissue factor in non-smallcell lung cancers and its relationship to metastasis. Br J Cancer 1999;79(3–4): 472–7. DOI: 10.1038/sj.bjc.6690073.Jiang X., Bailly M.A., Panetti T.S. et al. Formation of tissue factor-factor VIIafactor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost 2004;2(1):93–101. DOI: 10.1111/j.1538-7836.2004.00545.x.Jiang X., Bailly M.A., Panetti T.S. et al. Formation of tissue factor-factor VIIafactor Xa complex promotes cellular signaling and migration of human breast cancer cells. J Thromb Haemost 2004;2(1):93–101. DOI: 10.1111/j.1538-7836.2004.00545.x.Morris D.R., Ding Y., Ricks T.K. et al. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 2006;66(1):307–14. DOI: 10.1158/0008-5472.CAN-05-1735.Morris D.R., Ding Y., Ricks T.K. et al. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 2006;66(1):307–14. DOI: 10.1158/0008-5472.CAN-05-1735.Hjortoe G.M., Petersen L.C., Albrektsen T. et al. Tissue factor-factor VIIa-specific upregulation of IL-8 expression in MDAMB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004;103(8):3029–37. DOI: 10.1182/blood-2003-10-3417.Hjortoe G.M., Petersen L.C., Albrektsen T. et al. Tissue factor-factor VIIa-specific upregulation of IL-8 expression in MDAMB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004;103(8):3029–37. DOI: 10.1182/blood-2003-10-3417.Tieken C., Verboom M.C., Ruf W. et al. Tissue factor associates with survival and regulates tumour progression in osteosarcoma. Thromb Haemost 2016;115(5):1025–33. DOI: 10.1160/TH15-07-0541.Tieken C., Verboom M.C., Ruf W. et al. Tissue factor associates with survival and regulates tumour progression in osteosarcoma. Thromb Haemost 2016;115(5):1025–33. DOI: 10.1160/TH15-07-0541.Contrino J., Hair G., Kreutzer D.L., Rickles F.R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2(2):209–15.Contrino J., Hair G., Kreutzer D.L., Rickles F.R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2(2):209–15.Ettelaie C., Collier M.E., Featherby S. et al. Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression. Thromb J 2016;14:2. DOI: 10.1186/s12959-016-0075-3.Ettelaie C., Collier M.E., Featherby S. et al. Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression. Thromb J 2016;14:2. DOI: 10.1186/s12959-016-0075-3.Berny-Lang M.A., Aslan J.E., Tormoen G.W. et al. Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Phys Biol 2011;8(1):15014. DOI: 10.1088/1478-3975/8/1/015014.Berny-Lang M.A., Aslan J.E., Tormoen G.W. et al. Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Phys Biol 2011;8(1):15014. DOI: 10.1088/1478-3975/8/1/015014.Goldin-Lang P., Tran Q.V., Fichtner I. et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep 2008;20(1):123–8. DOI: 10.3892/or.20.1.123.Goldin-Lang P., Tran Q.V., Fichtner I. et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep 2008;20(1):123–8. DOI: 10.3892/or.20.1.123.Koomagi R., Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998;79(1):19–22. DOI: 10.1002/(SICI)1097-0215(19980220)79:1<19::AIDIJC4>3.0.CO;2-Z.Koomagi R., Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998;79(1):19–22. DOI: 10.1002/(SICI)1097-0215(19980220)79:1<19::AIDIJC4>3.0.CO;2-Z.Hobbs J.E., Zakarija A., Cundiff D.L. et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007;120(Suppl 2):13–21. DOI: 10.1016/S0049-3848(07)70126-3.Hobbs J.E., Zakarija A., Cundiff D.L. et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007;120(Suppl 2):13–21. DOI: 10.1016/S0049-3848(07)70126-3.Khorana A.A., Francis C.W., Menzies K.E. et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008;6(11):1983–5. DOI: 10.1111/j.1538-7836.2008.03156.x.Khorana A.A., Francis C.W., Menzies K.E. et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008;6(11):1983–5. DOI: 10.1111/j.1538-7836.2008.03156.x.Thomas G.M., Brill A., Mezouar S. et al. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost 2015;13(7):1310–9. DOI: 10.1111/jth.13002.Thomas G.M., Brill A., Mezouar S. et al. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost 2015;13(7):1310–9. DOI: 10.1111/jth.13002.Yu J.L., Rak J.W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004;2(11):2065–7. DOI: 10.1111/j.1538-7836.2004.00972.x.Yu J.L., Rak J.W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004;2(11):2065–7. DOI: 10.1111/j.1538-7836.2004.00972.x.Zhang J., Ding J., Zhang X. et al. Regulation of vascular endothelial growth factor (VEGF) production and angiogenesis by tissue Factor (TF) in SGC-7901 gastric cancer cells. Cancer Biol Ther 2005;4(7):769–72.Zhang J., Ding J., Zhang X. et al. Regulation of vascular endothelial growth factor (VEGF) production and angiogenesis by tissue Factor (TF) in SGC-7901 gastric cancer cells. Cancer Biol Ther 2005;4(7):769–72.Chand H.S., Ness S.A., Kisiel W. Identification of a novel human tissue factor splice variant that is upregulated in tumor cells. Int J Cancer 2006;118(7):1713–20. DOI: 10.1002/ijc.21550.Chand H.S., Ness S.A., Kisiel W. Identification of a novel human tissue factor splice variant that is upregulated in tumor cells. Int J Cancer 2006;118(7):1713–20. DOI: 10.1002/ijc.21550.Del Conde I., Shrimpton C.N., Thiagarajan P., Lopez J.A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005;106(5):1604–11. DOI: 10.1182/blood-2004-03-1095.Del Conde I., Shrimpton C.N., Thiagarajan P., Lopez J.A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005;106(5):1604–11. DOI: 10.1182/blood-2004-03-1095.Rauch U., Bonderman D., Bohrmann B. et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000;96(1):170–5.Rauch U., Bonderman D., Bohrmann B. et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000;96(1):170–5.Hisada Y., Auriemma A.C., Alexander W. et al. Detection of tissue factor-positive extracellular vesicles by laser scanning confocal microscopy. Thromb Res 2017;150:65–72. DOI: 10.1016/j.thromres.2016.12.021.Hisada Y., Auriemma A.C., Alexander W. et al. Detection of tissue factor-positive extracellular vesicles by laser scanning confocal microscopy. Thromb Res 2017;150:65–72. DOI: 10.1016/j.thromres.2016.12.021.Ichikawa J., Cole H.A., Magnussen R.A. et al. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma. Cancer 2012;118(9):2494–506. DOI: 10.1002/cncr.26518.Ichikawa J., Cole H.A., Magnussen R.A. et al. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma. Cancer 2012;118(9):2494–506. DOI: 10.1002/cncr.26518.Zhang Y., Deng Y., Luther T. et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94(3):1320–7. DOI: 10.1172/JCI117451.Zhang Y., Deng Y., Luther T. et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94(3):1320–7. DOI: 10.1172/JCI117451.Palumbo J.S., Talmage K.E., Massari J.V et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent andindependent mechanisms. Blood 2007;110(1):133–41. DOI: 10.1182/blood-2007-01-065995.Palumbo J.S., Talmage K.E., Massari J.V et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent andindependent mechanisms. Blood 2007;110(1):133–41. DOI: 10.1182/blood-2007-01-065995.Abe K., Shoji M., Chen J. et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96(15):8663–8. DOI: 10.1073/pnas.96.15.8663.Abe K., Shoji M., Chen J. et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96(15):8663–8. DOI: 10.1073/pnas.96.15.8663.Bromberg M.E., Sundaram R., Homer R.J. et al. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999;82(1):88–92.Bromberg M.E., Sundaram R., Homer R.J. et al. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999;82(1):88–92.